Sunshine Biopharma Inc
NASDAQ:SBFM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sunshine Biopharma Inc
Total Liabilities
Sunshine Biopharma Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sunshine Biopharma Inc
NASDAQ:SBFM
|
Total Liabilities
$7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
29%
|
CAGR 10-Years
19%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Total Liabilities
CA$2.4m
|
CAGR 3-Years
55%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Total Liabilities
$170.3m
|
CAGR 3-Years
38%
|
CAGR 5-Years
25%
|
CAGR 10-Years
29%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Total Liabilities
$51.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
24%
|
CAGR 10-Years
33%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Total Liabilities
CA$4.1m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Total Liabilities
$53.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sunshine Biopharma Inc
Glance View
Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. The company is headquartered in Pointe-Claire, Quebec and currently employs 3 full-time employees. The company went IPO on 2008-08-15. In addition, the Company is engaged in the development and commercialization of science-based nutritional supplements. The Company’s drug development operations include SBFM-PL4 Anti-Coronavirus Treatment and Adva-27a Anticancer Drug. The firm is engaged in the development of its Anti-Coronavirus compound, SBFM-PL4. The company is advancing the development of two compounds in parallel with its SBFM-PL4. The Company’s drug development activities have focused on the development of a small molecule, Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells, including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells.
See Also
What is Sunshine Biopharma Inc's Total Liabilities?
Total Liabilities
7m
USD
Based on the financial report for Dec 31, 2025, Sunshine Biopharma Inc's Total Liabilities amounts to 7m USD.
What is Sunshine Biopharma Inc's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
19%
Over the last year, the Total Liabilities growth was 0%. The average annual Total Liabilities growth rates for Sunshine Biopharma Inc have been -3% over the past three years , 29% over the past five years , and 19% over the past ten years .
